Oncogenic Fusions
- Summary
- Druggable NRG1 Gene Fusions as markers and targets for cancer.
- Technology Benefits
- CD74-NRG1 is a novel fusion gene which is used for diagnosis and as a target for medical intervention
MTSS1-NRG1 as another druggable oncogenic NRG1 fusion gene
Known Signalling Pathways
Enables stratification of patients for ERBB2 and/or ERBB3 inhibitor treatment
- Technology Application
- NRG1 gene fusions as ideal diagnostic and prognostic markers and targets for various tumours.
- Detailed Technology Description
- The MTSS1-NRG1 fusion event has e.g. been detected in patients with small cell lung cancer and the gene fusion CD74-NRG1 has been shown to occur frequently in never smokers with invasive mucinous lung adenocarcinoma lacking KRAS mutation. CD74-NRG1 was found to signal through induction of ERBB2-ERBB3 heterodimers. The detection of CD74-NRG1 fusions may aid making a decision on the appropriate medical treatment e.g. for invasive mucinous lung adenocarcinomas.
- Type of Cooperation
- Licensing
- Application Date
- 07/08/2014 00:00:00
- Application No.
- EP20140749817 20140807
- Classes
- - international:
C07K14/74; C07K14/82
- cooperative:
C07K14/4756; C07K14/70596; C12Q1/6886; C07K2319/00; C12Q2600/118; C12Q2600/158
- Others
- Patent application
- ID No.
- 3769
- Country/Region
- Germany
For more information, please click Here
